Axalta Coating Systems is generating stable returns on the same capital employed, not compounding earnings. Underlying trends suggest it may not be a potential multi-bagger. High return seekers may find better opportunities elsewhere.
Axalta Coating Systems is undervalued, suggesting a good time to buy more AXTA stock. The prosperous future outlook isn't fully reflected in the current price. Consider other factors like balance sheet strength before investing.
Investors in Axalta Coating Systems are expecting robust future growth, thus the high P/E ratio. A serious risk of earnings deterioration isn't seen likely and hence, a significant fall in share price seems unlikely.
Axalta Coating Systems' high debt usage to boost its ROE is worrying due to associated risks. Despite a fair ROE, the elevated debt level lacks appeal.
Axalta Coating Systems, with steady ROCE levels, doesn't seem to be reinvesting, indicating it might be past its growth stage. This limited return trend might be why its stock only gained 18% in the last five years, hinting at limited future high growth potential.
Axalta's leadership regards Mary Zappone's appointment positively, citing her broad expertise in critical sectors to the company's growth. Her CEO and chemical engineer experience is anticipated to significantly complement the board's capabilities.
Increased insider investment in Axalta Coating Systems indicates optimism for its future. Despite higher purchase prices, this shows belief in the stock’s value. However, some risks like the 1 warning sign remain.
Optimism in the market for Axalta Coating Systems Ltd is seen with EPS growth and increased share price. The company's positive outlook is boosted by insider investments, but risks remain to be considered before investing.
艾仕得涂料系统股票讨论区
5年来毛利率从33.9%下滑到29.1%,营业费用总体小幅减少。
2022年利息费用占营业利润的33%,利息压力极大。
目前34倍市盈率缺乏足够的成长数据支持。
专栏Today's pre-market stock movers: TWTR, UPS, HSBC, JBLU and more
• $Avadel Pharmaceuticals(AVDL.US)$ +36.1% (continued volatility)
• $Gamida Cell(GMDA.US)$ +20.57% (announces FDA clearance of investigational IND and removal of clinical hold for GDA-201)
• $Venator Materials(VNTR.US)$ +14.61% (VNTR receives $85 mln settlement from Tronox)
• $欧伊诺(OI.US)$ +10.9% (earnings report)
• $康宁(GLW.US)$ +9% (earnings report)
• $Arch Resources(ARCH.US)$ +7.2% (earnings report)
• $宣伟公司(SHW.US)$ +6.1% (ea...
暂无评论